Life-extension therapy: Nateglinide, a blood glucose-lowering drug, inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span, 14/January/2017, 4.29 pm

Natural product-derived PD-1 pathway blockade for Human cancer therapy: Persimmon tannin extract decreases the activity of Glycogen synthase kinase-3β, increases transcription factor T-bet expression, decreases the abundance of co-inhibitory receptor PD-1 on the cell surface of Cytotoxic-T-cells, increases cytotoxic T lymphocyte function and augments anti-tumor activity, via up-regulation of its target gene, 13/December/2016, 11.45 pm
January 13, 2017
Anticancer therapy targeting the cancer stem cells: MiRNA-9600 inhibits the expression of stem cell gene Oct-4, inhibits proliferation, and promotes apoptosis of cancer cells via down regulation of its target gene, 14/January/2016, 4.55 pm
January 14, 2017
Show all

What they say? 

A study from the Institute of Healthy Ageing, Centre for Diabetes and Endocrinology, Department of Medicine, University College London, London WC1E 6JJ, UK shows that “Ribosomal protein S6 kinase 1 signaling regulates mammalian life span.” This study was published in the 2 October 2009 issue of the Journal “Science” (I.F: 31.477 ) by Prof Dominic J. Withers, Dr. Selman C and others.


What we say

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMDreports, for the first time, that: Life-extension therapy: Nateglinide, a blood glucose-lowering drug, inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span


Research findings to Therapeutic opportunity: 

Nateglinide, by  increasing  the expression of its target gene, it may suppress Ribosomal protein S6 kinase 1 (p70S6 Kinase) expression. Thereby, it may promote: (1) resistance to bone, immune, and motor dysfunction; (2) insulin sensitivity; and (3) longevity (fig. 1).   

Nateglinide inhibits p70S6 kinase and extends mammalian lifespan

Fig 1. The glucose-lowering drug Nateglinide may function as a longevity promoter by suppressing the expression of p70 S6 Kinase

price-50[easy_payment currency=”USD”]

Thus, pharmacological formulations encompassing Nateglinide either alone or in combination with any of the known longevity-promoting compound(s) may be used to extend the lifespan of an individual (fig. 1).


Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic Information: How does  Nateglinide decrease the expression of p70 S6 Kinase and promote mammalian life span?

# Research cooperation

Amount: $50#

For purchase and payment information, you may reach us at info@genomediscovery.org


References:

CitationBoominathan, L.,  Life-extension therapy: Nateglinide, a blood glucose-lowering drug, inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span, 14/January/2017, 4.29 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or newbioideas.com/

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.